• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

TM4SF4 是一种诊断生物标志物，通过 AKT 通路加速甲状腺乳头状癌的进展。

TM4SF4 is a diagnostic biomarker accelerating progression of papillary thyroid cancer via AKT pathway.

机构信息

Department of Surgery, Clinical Sciences Lund, Lund University, Lund, Sweden.

Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

出版信息

Cancer Biol Ther. 2024 Dec 31;25(1):2424570. doi: 10.1080/15384047.2024.2424570. Epub 2024 Nov 4.

DOI:10.1080/15384047.2024.2424570
PMID:39497261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11540099/
Abstract

The incidence of papillary thyroid cancer (PTC) has been steadily rising, though the underlying mechanism remains unclear. This study aims to elucidate the biological role of TM4SF4 in the PTC progression. Our differential expression analysis indicated that TM4SF4 was significantly upregulated in PTC, which was corroborated in both our local cohort and the data from Human Protein Atlas. Additionally, clinical characteristics analysis and receiver operating characteristic curves (ROC) demonstrated that TM4SF4 served as a significant diagnostic marker for PTC. Correlation and enrichment analysis of TM4SF4-related partners suggested that it was involved in cell junction and cohesion processes. Furthermore, immune infiltration analysis revealed a positive correlation between TM4SF4 expression and the immune activation in PTC. Importantly, experiments demonstrated that TM4SF4 downregulation suppressed the proliferation and metastasis of PTC cell lines while inducing apoptosis. We further discovered that the AKT activator SC79 was able to reverse the malignant behaviors suppression caused by TM4SF4 knockdown, suggesting that TM4SF4 may promote PTC progression via the AKT pathway. In conclusion, our study highlights the oncogenic role of TM4SF4 in PTC and identifies it as a novel biomarker for diagnosis and treatment.

摘要

甲状腺乳头状癌 (PTC) 的发病率一直在稳步上升，但潜在的机制仍不清楚。本研究旨在阐明 TM4SF4 在 PTC 进展中的生物学作用。我们的差异表达分析表明，TM4SF4 在 PTC 中显著上调，这在我们的本地队列和人类蛋白质图谱的数据中都得到了证实。此外，临床特征分析和接收者操作特征曲线 (ROC) 表明 TM4SF4 是 PTC 的一个重要诊断标志物。TM4SF4 相关伙伴的相关性和富集分析表明，它参与了细胞连接和凝聚过程。此外，免疫浸润分析显示 TM4SF4 表达与 PTC 中的免疫激活呈正相关。重要的是，实验表明 TM4SF4 的下调抑制了 PTC 细胞系的增殖和转移，同时诱导了细胞凋亡。我们进一步发现 AKT 激活剂 SC79 能够逆转 TM4SF4 敲低引起的恶性行为抑制，表明 TM4SF4 可能通过 AKT 通路促进 PTC 进展。总之，本研究强调了 TM4SF4 在 PTC 中的致癌作用，并将其鉴定为诊断和治疗的新生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/d6a71cf05519/KCBT_A_2424570_F0009_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/faae59aba282/KCBT_A_2424570_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/2026e552c02b/KCBT_A_2424570_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/4ae7d5919c83/KCBT_A_2424570_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/61c80cf12012/KCBT_A_2424570_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/0cc4c0d42489/KCBT_A_2424570_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/c0bea0026349/KCBT_A_2424570_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/5b3621d67b63/KCBT_A_2424570_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/809f847a6104/KCBT_A_2424570_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/d6a71cf05519/KCBT_A_2424570_F0009_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/faae59aba282/KCBT_A_2424570_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/2026e552c02b/KCBT_A_2424570_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/4ae7d5919c83/KCBT_A_2424570_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/61c80cf12012/KCBT_A_2424570_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/0cc4c0d42489/KCBT_A_2424570_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/c0bea0026349/KCBT_A_2424570_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/5b3621d67b63/KCBT_A_2424570_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/809f847a6104/KCBT_A_2424570_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6e4/11540099/d6a71cf05519/KCBT_A_2424570_F0009_OC.jpg

相似文献

1
TM4SF4 is a diagnostic biomarker accelerating progression of papillary thyroid cancer via AKT pathway.TM4SF4 是一种诊断生物标志物，通过 AKT 通路加速甲状腺乳头状癌的进展。
Cancer Biol Ther. 2024 Dec 31;25(1):2424570. doi: 10.1080/15384047.2024.2424570. Epub 2024 Nov 4.
2
is a diagnostic and prognostic biomarker that promotes papillary thyroid cancer progression.是一种诊断和预后生物标志物，可促进甲状腺乳头状癌的进展。
Aging (Albany NY). 2020 Aug 28;12(16):16437-16456. doi: 10.18632/aging.103710.
3
MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.微小RNA-766通过直接靶向胰岛素受体底物2并调节PI3K/Akt信号通路来抑制甲状腺乳头状癌的进展。
Int J Oncol. 2019 Jan;54(1):315-325. doi: 10.3892/ijo.2018.4615. Epub 2018 Nov 1.
4
STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.STAT3 诱导的长链非编码 RNA ABHD11-AS1 的上调通过调节 miR-1301-3p/STAT3 轴和 PI3K/AKT 信号通路促进甲状腺乳头状癌的肿瘤进展。
Cell Prolif. 2019 Mar;52(2):e12569. doi: 10.1111/cpr.12569. Epub 2019 Jan 18.
5
Oncogenic pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR pathway.癌基因假基因 DUXAP10 敲低通过抑制 Akt/mTOR 通路抑制甲状腺乳头状癌细胞的增殖、侵袭并诱导其凋亡。
Clin Exp Pharmacol Physiol. 2020 Aug;47(8):1473-1483. doi: 10.1111/1440-1681.13310. Epub 2020 Apr 21.
6
Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.长链非编码 RNA 癌症易感性候选基因 2 通过失活 AKT/ERK1/2 信号通路抑制甲状腺乳头状癌生长。
J Cell Biochem. 2019 Jun;120(6):10380-10390. doi: 10.1002/jcb.28322. Epub 2019 Jan 4.
7
Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling.环状 RNA 0079558 通过与 miR-26b-5p 结合来激活 MET/AKT 信号通路，从而促进甲状腺乳头状癌的进展。
Endocr J. 2021 Nov 29;68(11):1247-1266. doi: 10.1507/endocrj.EJ20-0498. Epub 2021 Sep 25.
8
LncRNA PFAR facilitates the proliferation and migration of papillary thyroid carcinoma by competitively binding to miR-15a.长链非编码 RNA PFAR 通过与 miR-15a 竞争结合促进甲状腺乳头状癌的增殖和迁移。
Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3037-3048. doi: 10.1007/s00210-023-02779-w. Epub 2023 Oct 24.
9
MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.微小 RNA-26a 通过靶向 ROCK1 并调控 PI3K/AKT 信号通路抑制甲状腺乳头状癌细胞的恶性生物学行为。
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8940-8949. doi: 10.26355/eurrev_201910_19292.
10
LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.LHPP 通过调控 AKT/AMPK/mTOR 信号通路抑制甲状腺乳头状癌细胞生长和迁移并诱导自噬。
Acta Biochim Biophys Sin (Shanghai). 2020 Apr 20;52(4):382-389. doi: 10.1093/abbs/gmaa015.

本文引用的文献

1
A blueprint for tumor-infiltrating B cells across human cancers.一份关于人类癌症中肿瘤浸润性B细胞的蓝图。
Science. 2024 May 3;384(6695):eadj4857. doi: 10.1126/science.adj4857.
2
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.PI3K/Akt/mTOR 信号通路作为结直肠癌治疗的靶点。
Int J Mol Sci. 2024 Mar 9;25(6):3178. doi: 10.3390/ijms25063178.
3
SHMT2 promotes papillary thyroid cancer metastasis through epigenetic activation of AKT signaling.丝氨酸羟甲基转移酶2通过AKT信号通路的表观遗传激活促进甲状腺乳头状癌转移。
Cell Death Dis. 2024 Jan 25;15(1):87. doi: 10.1038/s41419-024-06476-1.
4
Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.调节性 T 细胞与三阴性乳腺癌的肿瘤免疫微环境和免疫治疗反应有关。
Front Immunol. 2023 Sep 12;14:1263537. doi: 10.3389/fimmu.2023.1263537. eCollection 2023.
5
Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma.靶向肝细胞癌中的表皮生长因子受体/磷脂酰肌醇-3激酶/蛋白激酶B/雷帕霉素靶蛋白信号通路
Pharmaceutics. 2023 Aug 14;15(8):2130. doi: 10.3390/pharmaceutics15082130.
6
Tumour-associated macrophages in gastric cancer: From function and mechanism to application.胃癌中的肿瘤相关巨噬细胞：从功能和机制到应用。
Clin Transl Med. 2023 Aug;13(8):e1386. doi: 10.1002/ctm2.1386.
7
NK cell-based tumor immunotherapy.基于自然杀伤细胞的肿瘤免疫疗法。
Bioact Mater. 2023 Aug 9;31:63-86. doi: 10.1016/j.bioactmat.2023.08.001. eCollection 2024 Jan.
8
Potential diagnostic of lymph node metastasis and prognostic values of TM4SFs in papillary thyroid carcinoma patients.TM4SFs在甲状腺乳头状癌患者中的淋巴结转移潜在诊断价值及预后价值
Front Cell Dev Biol. 2022 Dec 8;10:1001954. doi: 10.3389/fcell.2022.1001954. eCollection 2022.
9
A prognostic nomogram for papillary thyroid cancer lymph node metastasis based on immune score.基于免疫评分的甲状腺乳头状癌淋巴结转移预后列线图
Front Endocrinol (Lausanne). 2022 Dec 1;13:993856. doi: 10.3389/fendo.2022.993856. eCollection 2022.
10
Targeting PI3K/Akt signaling in prostate cancer therapy.在前列腺癌治疗中靶向PI3K/Akt信号通路
J Cell Commun Signal. 2023 Sep;17(3):423-443. doi: 10.1007/s12079-022-00702-1. Epub 2022 Nov 11.